Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Points to consider in renal involvement in systemic sclerosis.

Felice Galluccio1, Ulf Müller-Ladner2,3, Daniel E Furst4

  • 1Department of Clinical and Experimental Medicine, Division of Rheumatology, University of Florence, AOU Careggi, Florence, Italy.

Rheumatology (Oxford, England)
|October 10, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement.

Seminars in arthritis and rheumatism·2026
Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026
Same author

Integrated transcriptomic and epigenomic profiling reveals conserved molecular subtypes across systemic autoimmune diseases.

Annals of the rheumatic diseases·2026
Same author

Integrated single-cell transcriptomic analysis identifies <i>PF4</i> <sup><i>+</i></sup> <i>/PPBP</i> <sup><i>+</i></sup> megakaryocyte-like granulocytes associated with immune dysregulation in autoimmune diseases.

Biochemistry and biophysics reports·2026
Same author

Serum KL-6 and lung ultrasound B-lines: a combined non-invasive model for screening and predicting interstitial lung disease in idiopathic inflammatory myopathy.

RMD open·2026
Same author

Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study.

Seminars in arthritis and rheumatism·2026

Designing clinical trials for systemic sclerosis (SSc) renal involvement requires careful consideration of trial design, patient criteria, and outcome measures. Key factors include using randomized controlled trials and defining specific renal function parameters for accurate therapeutic evaluation.

Area of Science:

  • Nephrology
  • Rheumatology
  • Clinical Trial Design

Background:

  • Systemic sclerosis (SSc) frequently involves renal complications, necessitating effective therapeutic strategies.
  • Current clinical trial designs for SSc renal involvement require optimization for robust evidence generation.

Purpose of the Study:

  • To outline critical considerations for designing clinical trials evaluating therapies for renal involvement in SSc, excluding scleroderma renal crisis.
  • To provide guidance on methodological aspects to enhance the validity and reliability of trial outcomes.

Main Methods:

  • Recommends double-blind, randomized controlled trials (RCTs) comparing interventions against placebo or standard care.
  • Suggests defining clear inclusion criteria based on pre-specified renal function ranges or stratification.
Keywords:
clinical trialskidneypoints to considerrenalsystemic sclerosis

Related Experiment Videos

  • Emphasizes the need to account for concomitant medications and confounding comorbidities.

    • Main Results:

    • RCTs are the preferred design for evaluating SSc renal therapies.
    • Stratification by renal function and careful consideration of confounding factors are crucial.
    • Validated renal function measures, time to dialysis, mortality, and disease progression are potential outcome measures.

    Conclusions:

    • Robust clinical trial design is essential for advancing SSc renal involvement therapies.
    • Standardized methodologies and comprehensive data analysis, including handling missing data, are vital.
    • Future trials should focus on validated endpoints and rigorous statistical planning.